Lupin concludes USFDA inspection at Pithampur facility without any observations

29 Jul 2017 Evaluate

Lupin has successfully completed GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Pithampur manufacturing facility - Unit 1 without any observations. The inspection which started on July 24, 2017 concluded on July 28, 2017.

Earlier, USFDA had successfully completed PAI at company’s Goa manufacturing facility without any observations. The inspection which started on July 17 concluded on July 21, 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.



Lupin Share Price

2124.65 -26.40 (-1.23%)
01-Feb-2026 14:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1613.85
Dr. Reddys Lab 1202.25
Cipla 1326.00
Zydus Lifesciences 887.40
Lupin 2124.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×